{"id":197064,"name":"GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICS","slug":"government-counsel-llc-obo-prime-therapeutics","state":"FL","country":"United States of America","description":"&#226;€‹Public Policy and Government Advisory Firm","totalSpending":280000,"filings":29,"yearlySpending":[{"year":2019,"income":40000},{"year":2020,"income":40000},{"year":2021,"income":40000},{"year":2022,"income":40000},{"year":2023,"income":40000},{"year":2024,"income":40000},{"year":2025,"income":40000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["HOOPER, LUNDY & BOOKMAN, P.C."],"lobbyists":["MARTIN CORRY","LISA LAYMAN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues relating to pharmaceutical value-based contracting and rebate transparency.","Provisions affecting market competition for prescription drugs and the drug supply chain; provisions related to rebates at the point of sale; provisions related to pharmacist direct and indirect remun","Provisions affecting market competition for prescription drugs and the drug supply chain; HHS Blueprint to lower drug prices and reduce out-of-pocket costs; The Creating and Restoring Equal Access to ","Provisions affecting market competition for prescription drugs and the drug supply chain; The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965); The Phair Prici","Provisions related to price transparency rebates and spread pricing; Provisions related to pharmacist direct and indirect remuneration; The Prescription Drug Price Transparency Act (H.R. 1035); The Ph"]}